Expression of Vascular Endothelial Growth Factor in Taiwanese Benign and Malignant Prostate Tissues

Folkman, 1990, What is the evidence that tumours are angiogenesis dependent?, J Natl Cancer Inst, 82, 4, 10.1093/jnci/82.1.4 Senger, 1993, Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid, Science, 219, 983, 10.1126/science.6823562 Connolly, 1989, Tumour vascular permeability factor stimulates endothelial cell growth and angiogenesis, J Clin Invest, 84, 470, 10.1172/JCI114322 Ferrara, 1998, The biology of vascular endothelial growth factor, Endocr Rev, 18, 4, 10.1210/edrv.18.1.0287 Dvorak, 1995, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis, Am J Pathol, 146, 1029 Takahashi, 1995, Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer, Cancer Res, 55, 3964 Toi, 1995, Tumour angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression, Breast Cancer Res Treat, 36, 193, 10.1007/BF00666040 Maeda, 1996, Prognostic value of vascular endothe-lial growth factor expression in gastric carcinoma, Cancer, 7, 858, 10.1002/(SICI)1097-0142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-A West, 2001, Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer, Br J Cancer, 85, 576, 10.1054/bjoc.2001.1971 Köllermann, 2001, Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue, Am J Clin Pathol, 116, 115, 10.1309/1LBM-6X32-JH6W-ENUD Walsh, 2002, Distribution of vascular endothelial growth factor (VEGF) in prostate disease, Prostate Cancer Prostatic Dis, 5, 119, 10.1038/sj.pcan.4500575 Jackson, 1997, Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign pro-static hyperplasia, J Urol, 157, 2323, 10.1016/S0022-5347(01)64774-8 Joseph, 1997, Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers, Cancer Res, 57, 1054 Yang, 2006, Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression, Asian J Androl, 8, 169, 10.1111/j.1745-7262.2006.00120.x Ferrer, 1999, Expression of vascular endothelial growth factor receptors in human prostate cancer, Urology, 54, 567, 10.1016/S0090-4295(99)00156-9 Claffey, 1996, Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis, Cancer Metast Rev, 15, 165, 10.1007/BF00437469 Terman, 1996, Biological properties of VEGF/VPF receptors, Cancer Metast Rev, 15, 159, 10.1007/BF00437468 Kung, 2006, Expression of c-kit, Flk-1, and Flk-2 receptors in benign and malignant tumors of follicular epithelial origin, J Chin Med Assoc, 69, 74, 10.1016/S1726-4901(09)70117-0 Kwak, 2002, Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia, BJU Int, 89, 303, 10.1046/j.1464-4096.2001.01417.x Harper, 1996, Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells, Br J Cancer, 74, 910, 10.1038/bjc.1996.456 Borre, 2000, Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumour cells, and outcome in prostate cancer patients subjected to watchful waiting, Clin Cancer Res, 6, 1882 Ferrer, 1997, Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells, J Urol, 157, 2329, 10.1016/S0022-5347(01)64775-X